LEE'S PHARM (00950) has announced its interim results for 2026, posting a revenue of approximately HK$797 million, marking a year-on-year increase of 14.6%.

The company recorded a profit attributable to owners of HK$95.014 million, up 41.4% from the previous corresponding period, with earnings per share standing at HK16.14 cents. An interim dividend of HK3.5 cents per share has been declared.

Revenue from licensed-in products climbed 24.3% to around HK$337 million, driven primarily by contributions from Ferplex®, Bredinin®, Trerief®, and Ruishuyan®.

Meanwhile, revenue from proprietary and generic products grew 8.4% to HK$459 million, buoyed by sales of Socazolimab injection Shanke® (following the addition of the extensive-stage small cell lung cancer indication), Yujing'an®, treprostinil injection Ruinier®, azilsartan tablets Qitanping®, and fondaparinux sodium injection Lichangqing®. These gains helped offset the decline in nadroparin calcium injection Litengjing®, which was impacted by centralised volume-based procurement pricing.